Emerging Raf inhibitors.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The Raf/MAPK kinase/extracellular-signal-regulated kinase pathway is frequently activated in cancers due to genetic alterations.
• BRAF mutations are common drivers, particularly in melanoma and thyroid cancers, impacting cell proliferation and drug sensitivity.
• This pathway influences critical cellular processes including proliferation, apoptosis, and differentiation.

Purpose of the Study:

• To review the therapeutic potential of targeting Raf for controlling abnormal cell proliferation in various diseases.
• To evaluate the role of patient genetics in determining response to Raf inhibitors.
• To explore the rationale for combining Raf inhibitors with chemotherapy.

Main Methods:

• Literature review of Raf inhibitors and their clinical applications.
• Analysis of genetic alterations affecting Raf pathway signaling.
• Evaluation of combination therapy strategies involving Raf inhibitors and chemotherapeutic agents.

Main Results:

• Raf inhibitors are clinically utilized for melanoma, thyroid, hepatocellular, and renal cell cancers.
• Both broad-spectrum and specific Raf inhibitors demonstrate efficacy, particularly in tumors with identified Raf mutations.
• The development of Raf inhibitors has marked significant progress in cancer therapy over the last decade.

Conclusions:

• Targeting the Raf pathway offers a viable strategy for managing proliferative diseases and cancers.
• Genetic profiling is crucial for predicting patient response to Raf-targeted therapies.
• Combination approaches with chemotherapy may enhance therapeutic benefits in specific cancer contexts.